{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T09:05:52Z","timestamp":1790240752524,"version":"4.1.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,4]],"date-time":"2020-08-04T00:00:00Z","timestamp":1596499200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.nano.2020.102275","type":"journal-article","created":{"date-parts":[[2020,8,2]],"date-time":"2020-08-02T01:49:13Z","timestamp":1596332953000},"page":"102275","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Pharmacokinetics, drug metabolism, and tissue distribution of CPX-351 in animals"],"prefix":"10.1016","volume":"30","author":[{"given":"Qi","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Tardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Sadowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherwin","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Heller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nano.2020.102275_bb0005","unstructured":"VYXEOS\u00ae (daunorubicin and cytarabine injection), solution for intravenous use [package insert]. Palo Alto, CA; Jazz Pharmaceuticals, Inc. 2019."},{"issue":"26","key":"10.1016\/j.nano.2020.102275_bb0010","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia","volume":"36","author":"Lancet","year":"2018","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.nano.2020.102275_bb0015","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.leukres.2012.07.006","article-title":"Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia","volume":"36","author":"Feldman","year":"2012","journal-title":"Leuk Res"},{"issue":"7","key":"10.1016\/j.nano.2020.102275_bb0020","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1002\/jps.21620","article-title":"Pharmacokinetics of CPX-351 (cytarabine\/daunorubicin HCl) liposome injection in the mouse","volume":"98","author":"Bayne","year":"2009","journal-title":"J Pharm Sci"},{"issue":"1\u20132","key":"10.1016\/j.nano.2020.102275_bb0025","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ijpharm.2010.02.014","article-title":"Biophysical characterization of a liposomal formulation of cytarabine and daunorubicin","volume":"391","author":"Dicko","year":"2010","journal-title":"Int J Pharm"},{"issue":"1","key":"10.1016\/j.nano.2020.102275_bb0030","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.leukres.2008.06.028","article-title":"In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy","volume":"33","author":"Tardi","year":"2009","journal-title":"Leuk Res"},{"issue":"9","key":"10.1016\/j.nano.2020.102275_bb0035","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.leukres.2010.01.015","article-title":"Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts","volume":"34","author":"Lim","year":"2010","journal-title":"Leuk Res"},{"issue":"2\u20133","key":"10.1016\/j.nano.2020.102275_bb0040","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0169-409X(95)00029-7","article-title":"Pharmacokinetics of long-circulating liposomes","volume":"16","author":"Allen","year":"1995","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"10.1016\/j.nano.2020.102275_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0304-4165(85)90174-6","article-title":"Tissue distribution of liposomes exhibiting long half-lives in the circulation after intravenous injection","volume":"839","author":"Senior","year":"1985","journal-title":"Biochim Biophys Acta"},{"issue":"5","key":"10.1016\/j.nano.2020.102275_bb0050","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/jcph.1366","article-title":"Population pharmacokinetics and exposure-response analyses for CPX-351 in patients with hematologic malignancies","volume":"59","author":"Wang","year":"2019","journal-title":"J Clin Pharmacol"},{"issue":"7","key":"10.1016\/j.nano.2020.102275_bb0055","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1158\/1535-7163.MCT-06-0118","article-title":"Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice","volume":"5","author":"Mayer","year":"2006","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"10.1016\/j.nano.2020.102275_bb0060","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.3109\/10428194.2010.490312","article-title":"Schedule- and dose-dependency of CPX-351, a synergistic fixed ratio cytarabine:daunorubicin formulation, in consolidation treatment against human leukemia xenografts","volume":"51","author":"Lim","year":"2010","journal-title":"Leuk Lymphoma"},{"issue":"19","key":"10.1016\/j.nano.2020.102275_bb0065","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1016\/0006-2952(73)90342-0","article-title":"Pharmacokinetics of 1-\u03b2-d-arabinofuranosylcytosine (Ara-C) deamination in several species","volume":"22","author":"Dedrick","year":"1973","journal-title":"Biochem Pharmacol"},{"issue":"9","key":"10.1016\/j.nano.2020.102275_bb0070","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1080\/1061186X.2016.1184669","article-title":"Passive and semi-active targeting of bone marrow and leukemia cells using anionic low cholesterol liposomes","volume":"24","author":"Tardi","year":"2016","journal-title":"J Drug Target"},{"key":"10.1016\/j.nano.2020.102275_bb0075","first-page":"1","article-title":"Scavenger receptor class BI (SR-BI) mediates uptake of CPX-351 into K562 leukemia cells","author":"Di","year":"2018","journal-title":"Drug Dev Ind Pharm"},{"key":"10.1016\/j.nano.2020.102275_bb0080","series-title":"Highlights of Prescribing Information. VYXEOS (daunorubicin and cytarabine) liposome for injection, for intravenous use","author":"U.S. Food and Drugs Administration","year":"2017"},{"issue":"8","key":"10.1016\/j.nano.2020.102275_bb0085","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1182\/blood.V88.8.2841.bloodjournal8882841","article-title":"A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a southwest oncology group study","volume":"88","author":"Weick","year":"1996","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.nano.2020.102275_bb0090","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.hfc.2011.03.001","article-title":"A historical perspective of anthracycline cardiotoxicity","volume":"7","author":"Ewer","year":"2011","journal-title":"Heart Fail Clin"},{"issue":"Suppl 2","key":"10.1016\/j.nano.2020.102275_bb0095","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1634\/theoncologist.8-suppl_2-17","article-title":"Cardiac safety of liposomal anthracyclines","volume":"8","author":"Safra","year":"2003","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.nano.2020.102275_bb0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0058421","article-title":"Comparative cardiac toxicity of anthracyclines in vitro and in vivo in the mouse","volume":"8","author":"Toldo","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.nano.2020.102275_bb0105","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00280-019-03856-9","article-title":"A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemias","volume":"84","author":"Lin","year":"2019","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963420301295?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963420301295?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T07:11:23Z","timestamp":1761549083000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1549963420301295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":21,"alternative-id":["S1549963420301295"],"URL":"https:\/\/doi.org\/10.1016\/j.nano.2020.102275","relation":{},"ISSN":["1549-9634"],"issn-type":[{"value":"1549-9634","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetics, drug metabolism, and tissue distribution of CPX-351 in animals","name":"articletitle","label":"Article Title"},{"value":"Nanomedicine: Nanotechnology, Biology and Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nano.2020.102275","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102275"}}